Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11069 Views
-
Last post by NHE
-
- 0 Replies
- 1034 Views
-
Last post by NHE
-
- 0 Replies
- 1826 Views
-
Last post by frodo
-
- 0 Replies
- 1175 Views
-
Last post by frodo
-
- 0 Replies
- 1966 Views
-
Last post by NHE
-
- 0 Replies
- 1646 Views
-
Last post by frodo
-
- 0 Replies
- 1172 Views
-
Last post by NHE
-
- 1 Replies
- 1609 Views
-
Last post by frodo
-
- 0 Replies
- 2220 Views
-
Last post by NHE